Lower-than-predicted Mortality in a Predominantly HIV-infected Population with Epidermal Necrolysis Regardless of HIV Status: Implications and Challenges for Interventional Studies

Overview

Journal J Allergy Clin Immunol Pract

Specialty Allergy & Immunology

Date 2018 Nov 19

PMID 30448502

Citations 3

Authors

Rannakoe J Lehloenya

Niita Haitembu

Wisdom Basera

Jonny Peter

Affiliations

Soon will be listed here.

Citing Articles

Cyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments.

Nazerian A, Jafarzadeh A, Salehi S, Ghasemi M, Goodarzi A Inflammopharmacology. 2024; 33(2):485-503.

PMID: 39470865 DOI: 10.1007/s10787-024-01590-0.

SJS/TEN 2019: From science to translation.

Chang W, Abe R, Anderson P, Anderson W, Ardern-Jones M, Beachkofsky T J Dermatol Sci. 2020; 98(1):2-12.

PMID: 32192826 PMC: 7261636. DOI: 10.1016/j.jdermsci.2020.02.003.

Drug hypersensitivity in HIV infection.

Peter J, Choshi P, Lehloenya R Curr Opin Allergy Clin Immunol. 2019; 19(4):272-282.

PMID: 31145192 PMC: 7236403. DOI: 10.1097/ACI.0000000000000545.

References

Mayosi B, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F . Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014; 371(12):1121-30. PMC: 4912834. DOI: 10.1056/NEJMoa1407380. View

Bansal S, Garg V, Sardana K, Sarkar R . A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis. Int J Dermatol. 2014; 54(1):e18-26. DOI: 10.1111/ijd.12466. View

Knight L, Muloiwa R, Dlamini S, Lehloenya R . Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis. PLoS One. 2014; 9(4):e93543. PMC: 3973591. DOI: 10.1371/journal.pone.0093543. View

Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau J, Kardaun S . Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011; 32(2):237-45. DOI: 10.1097/BCR.0b013e31820aafbc. View

Husain N, Ahmed M, Almobarak A, Noor S, Elmadhoun W, Awadalla H . HIV-Associated Nephropathy in Africa: Pathology, Clinical Presentation and Strategy for Prevention. J Clin Med Res. 2017; 10(1):1-8. PMC: 5722038. DOI: 10.14740/jocmr3235w. View

Hung C, Liu W, Kuo M, Lee C, Hwang S, Chen H . Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009; 29(6):633-8. DOI: 10.1159/000195632. View

White K, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B . SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. J Allergy Clin Immunol Pract. 2018; 6(1):38-69. PMC: 5857362. DOI: 10.1016/j.jaip.2017.11.023. View

Lehloenya R, Todd G, Badri M, Dheda K . Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J Tuberc Lung Dis. 2011; 15(12):1649-57. DOI: 10.5588/ijtld.10.0698. View

Gonzalez-Herrada C, Rodriguez-Martin S, Cachafeiro L, Lerma V, Gonzalez O, Lorente J . Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J Invest Dermatol. 2017; 137(10):2092-2100. DOI: 10.1016/j.jid.2017.05.022. View

10.

Roujeau J, Mockenhaupt M, Guillaume J, Revuz J . New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. J Invest Dermatol. 2017; 137(10):2047-2049. DOI: 10.1016/j.jid.2017.07.828. View

11.

Wang C, Yang L, Chen C, Ho H, Hung S, Yang C . Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018; 128(3):985-996. PMC: 5824923. DOI: 10.1172/JCI93349. View

12.

Wolkenstein P, Latarjet J, Roujeau J, Duguet C, Boudeau S, Vaillant L . Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998; 352(9140):1586-9. DOI: 10.1016/S0140-6736(98)02197-7. View